Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? / E.R. Haspinger, M.C. Garassino, V. Torri, M. Cinquini, F. De Braud, F. Gelsomino. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32:8(2014 Mar), pp. 859-863. [10.1200/JCO.2013.52.8794]
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
F. De BraudPenultimo
;
2014
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
DeBraud_JClinicalOncology_WeReallyNeed_ 2014.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
77.7 kB
Formato
Adobe PDF
|
77.7 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
